Clarus Ventures appeared to be the VC, which was created in 2005. The company was established in North America in United States. The main office of represented VC is situated in the Cambridge.
The fund is constantly included in 2-6 investment rounds annually. The higher amount of exits for fund were in 2013. The usual things for fund are deals in the range of 10 - 50 millions dollars. Comparing to the other companies, this Clarus Ventures performs on 1 percentage points more the average number of lead investments. The high activity for fund was in 2010. Considering the real fund results, this VC is 21 percentage points more often commits exit comparing to other organizations.
The fund was created by David Field. The overall number of key employees were 7.
The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Clarus Ventures, startups are often financed by SV Health Investors, New Leaf Venture Partners, 5AM Ventures. The meaningful sponsors for the fund in investment in the same round are 5AM Ventures, New Leaf Venture Partners, OrbiMed. In the next rounds fund is usually obtained by New Leaf Venture Partners, 5AM Ventures, SV Health Investors.
Among the various public portfolio startups of the fund, we may underline Annexon Biosciences, TetraLogic Pharmaceuticals, Aerovance For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Among the most popular fund investment industries, there are Medical, Therapeutics. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.
Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Galera Therapeutics | $70M | 19 Sep 2018 | Pennsylvania, United States | ||
Avrobio | $60M | 01 Feb 2018 | Cambridge, Massachusetts, United States | ||
$75M | 17 Oct 2017 | Palo Alto, California, United States | |||
Gritstone Oncology | $93M | 07 Sep 2017 | California, United States | ||
Cleave Therapeutics | $37M | 17 Aug 2016 | San Francisco, California, United States | ||
Avrobio | $25M | 02 Aug 2016 | Cambridge, Massachusetts, United States | ||
Annexon Biosciences | $44M | 23 Jun 2016 | South San Francisco, California, United States | ||
GrayBug | $44M | 02 May 2016 | Baltimore, Maryland, United States | ||
Lumos Pharma | $34M | 06 Apr 2016 | Austin, Texas, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Galera Therapeutics | $70M | 19 Sep 2018 | Pennsylvania, United States | ||
Avrobio | $60M | 01 Feb 2018 | Cambridge, Massachusetts, United States | ||
$75M | 17 Oct 2017 | Palo Alto, California, United States | |||
Gritstone Oncology | $93M | 07 Sep 2017 | California, United States | ||
Cleave Therapeutics | $37M | 17 Aug 2016 | San Francisco, California, United States | ||
Avrobio | $25M | 02 Aug 2016 | Cambridge, Massachusetts, United States | ||
Annexon Biosciences | $44M | 23 Jun 2016 | South San Francisco, California, United States | ||
GrayBug | $44M | 02 May 2016 | Baltimore, Maryland, United States | ||
Lumos Pharma | $34M | 06 Apr 2016 | Austin, Texas, United States |